Several new studies show very promising results in using intravenous (IV) plasma from “young donors” to treat Parkinson’s, Alzheimer’s, and other neurodegenerative diseases, as well as offer some other remarkable antiaging benefits. Young fresh frozen plasma (yFFP) contains the perfect blend of vital proteins, antioxidants and extracellular vehicles (EVs), which a recent and current study seem to indicate are able to rejuvenate body and brain tissues and fight the ravages of aging.
Umbilical or young plasma transfusions are not new. They have been the standard treatments to replace missing proteins in people with rare genetic diseases. However, what is new is investigations into how such transfers or IV infusions can be used to slow or reverse what is known as “epigenetic aging.” Your “epigenetic clock” is based on an ongoing biological process known as DNA methylation. It is a process of the modification of gene expression by the addition of methyl groups into the structure of your DNA as you age. DNA methylation levels form the basis of the epigenetic clock – a highly accurate marker of aging, sort of like rings on a tree. This so-called “Pace of Aging” is measured in clinical trials investigating antiaging interventions by something known as “DunedinPACE,” which is a highly accurate and reliable single-time-point measure of methylation levels in DNA.
While young blood plasma has previously been shown to have rejuvenating effects in animals, these are some of the first studies to examine these effects at the epigenetic level across multiple tissues and specifically on how yFFP infusions can improve Parkinson’s symptoms.
The Studies on the Benefits of Young Plasma Infusion
The principal investigator on these studies is the Principal Investigator is Dian Ginsberg, MD. Obstetrics, Gynecology & Functional and Antiaging Medicine. She is Certified in Antiaging and Regenerative Medicine and holds an Advanced Fellowship Metabolic Medical Institute Advisory Board.
Dr. Ginsberg has concluded a study that began in 2018 on the benefits of young plasma infusions for Parkinson’s patients and is involved in an ongoing study on how yFFP can slow or reverse your “epigenetic clock.”
Takeaways From Two Key Studies
- 2019 Intravenous Plasma (yFFP) Treatment for Parkinson’s Disease Study
- This is the first study of its kind to investigate the direct impact
- This study presents evidence that the administration of Young Fresh Frozen Plasma significantly improves multiple outcome measures during the 24 weeks after administration.
- The comparisons of those administered IV Young Plasma showed statistically significant improvements in unified Parkinson’s disease rating scale (UPDRS) scores when compared to placebo.
- Critical disease-related conditions such as fatigue, depression, and activities of daily living vs control saw statistically significant improvements.
- Laboratory parameters did not show that the patients had any harmful effects from the plasma.
You can download a PDF of the complete study authored by Dian J Ginsberg, MD, and Carl Scheffey by clicking on this link.
- ONGOING Investigational yFFP® Treatments Study
- Study approved in 2022
- Treatments CURRENTLY occurring in clinics throughout TX
- Employs Epigenetic Methylation, Genomic testing, and blood laboratory parameters
- Tracking biologic age shifts and genome changes
- Using sex and blood-typed Fresh Frozen Plasma from donors 18-25 years old, drawn at an AABB-accredited facility.
- Investigating the therapeutic use of yFFP across a wide spectrum of conditions, including Parkinson’s, Alzheimer’s, metabolic syndrome, and cardiovascular disease.
- Preliminary results show promise. For example, a 67-year-old male participating in the study with Parkinson’s disease received 2.5 liters of yFFP through three exchanges within thirty days. In four months, his DunedinPACE was reduced by 18% to 0.82!
